{"id":37712,"date":"2026-05-19T10:25:00","date_gmt":"2026-05-19T14:25:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37712"},"modified":"2026-03-29T15:05:29","modified_gmt":"2026-03-29T19:05:29","slug":"europes-divisional-patent-trap-how-big-pharma-delays-generics-without-ever-losing-in-court","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/europes-divisional-patent-trap-how-big-pharma-delays-generics-without-ever-losing-in-court\/","title":{"rendered":"Europe’s Divisional Patent Trap: How Big Pharma Delays Generics Without Ever Losing in Court"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

When a European patent dies \u2014 formally, irrevocably, at the hands of the European Patent Office’s Technical Board of Appeal \u2014 something commercially catastrophic happens. The decision enters the record. It becomes searchable. Generic manufacturers and their lawyers can cite it. Injunctions dissolve. The clock on exclusivity, once stopped, will not restart.<\/p>\n\n\n\n

This is precisely why that final decision almost never comes.<\/p>\n\n\n\n

Inside the EPO’s procedural machinery sits a mechanism that pharmaceutical originators have turned into one of their most effective competitive weapons: the divisional patent application. The theory behind divisionals is straightforward enough \u2014 a patentee files a broad “parent” application and later carves out distinct inventions into separate “child” filings, each entitled to the parent’s priority date. The practice looks nothing like the theory. What actually happens, across dozens of high-revenue drug franchises and multiple patent generations, is a controlled cascade of filings designed not to protect new inventions but to ensure that no court or examining body ever reaches the words “this application is refused.”<\/p>\n\n\n\n

The strategy exploits a structural feature of the EPO system: under the European Patent Convention, a divisional application can be filed from any pending application. File a divisional. If that divisional faces likely rejection, file a divisional from the divisional. The “grandchild” keeps the original priority date. It faces the same examination process. When that one nears a final adverse decision, file again. Each generation resets the procedural clock. The drug stays legally ambiguous. Generic entry stays legally risky.<\/p>\n\n\n\n

What you end up with, in practice, is a situation where a patent family for a blockbuster drug can contain thirty, forty, or sixty active members \u2014 many of them covering trivially different aspects of the same compound or formulation \u2014 none of which has ever received a final rejection. The compound’s core exclusivity has long since expired. But the question “can a generic legally enter this market right now?” remains unanswerable, and that uncertainty is worth hundreds of millions of euros in delayed competition.<\/p>\n\n\n\n

This piece maps how the strategy works mechanically, why the EPO’s successive reform attempts have not solved it, what it costs healthcare systems, and what real reform would require.<\/p>\n\n\n\n

\n\n\n\n

How the European Divisional System Works \u2014 And How It Gets Weaponized<\/strong><\/h2>\n\n\n\n

The EPC Framework and Rule 36<\/strong><\/h3>\n\n\n\n

The European Patent Convention, which established the EPO as the continent’s centralised examination body, contains provisions allowing applicants to divide their applications into separate filings. Article 76 EPC is the governing provision. Rule 36 of the Implementing Regulations sets the operational parameters.<\/p>\n\n\n\n

The original rationale was legitimate. An inventor might file a broad application claiming several independently patentable inventions. The EPO’s unity-of-invention doctrine (Rule 44 EPC) might require those inventions to be separated. The divisional mechanism lets the applicant comply without losing priority date coverage on distinct innovations. This is standard patent procedure across most major jurisdictions.<\/p>\n\n\n\n

The EPO’s rules allow a divisional to be filed at any time while the parent application remains pending. This single feature \u2014 pendency-linked filing rights \u2014 is what transforms the divisional mechanism from a housekeeping tool into a delay engine. As long as you keep at least one application from the family alive and pending, you retain the right to spawn new divisionals. Each new divisional is, on its face, a distinct application that must proceed through examination on its own schedule.<\/p>\n\n\n\n

In 2010, the EPO attempted to limit abuse by imposing a 24-month time window within which divisionals could be filed, measured from certain examining-division communications. The amendment created something close to the opposite of the intended effect: applicants simply filed divisionals immediately upon receiving any qualifying communication, regardless of the substantive merits of the new application. The 2014 revision removed the 24-month rule altogether and returned to the prior open-ended system, having concluded that the restriction had generated procedural chaos without materially reducing strategic filing.<\/p>\n\n\n\n

What remained was the open right to file divisionals indefinitely, subject only to the requirement of a pending parent.<\/p>\n\n\n\n

The Cascade Mechanics<\/strong><\/h3>\n\n\n\n

A strategic divisional cascade operates in stages. Stage one is the original broad filing, typically made at the national level or at the EPO, covering the core compound, its synthesis, its biological activity, and as many downstream applications as the applicant can articulate. This is filed around the time of clinical development, often before regulatory approval. The twenty-year patent term runs from this priority date.<\/p>\n\n\n\n

Stage two begins as the core patent reaches the end of its term or faces serious invalidity challenges \u2014 opposition proceedings, national court attacks, inter partes validity challenges. At this point, the originator files divisionals covering formulations, dosing regimens, metabolites, polymorphs, enantiomers, or methods of treatment. These are sometimes called “secondary patents” or “evergreening” patents, though those terms are inexact: divisionals need not claim patentably distinct inventions, and many of these filings would be rejected outright \u2014 if examined to a conclusion.<\/p>\n\n\n\n

Stage three is where the delay strategy becomes explicit. As each divisional approaches a final adverse decision \u2014 a refusal by the examining division, or an impending Technical Board of Appeal ruling \u2014 the applicant files one or more new divisionals from that application. The original divisional may ultimately be refused, or may be abandoned by the applicant, but the new generation of divisionals is now pending and examination begins again. The adverse decision that would have created a legal record remains off the books. The only record that exists is of pending applications: legally uncertain, potentially valid, impossible for generics to design around with confidence.<\/p>\n\n\n\n

The EPO’s own patent quality studies have documented the existence of families where single priority dates support twenty or more divisional children. Researchers at the Universities of Geneva and Zurich examining pharmaceutical patent families found that originator companies were filing significantly more divisionals per priority date than non-pharmaceutical applicants, with the disparity most pronounced in the years after core compound patents came under challenge. The EPO’s annual reports show pharmaceutical sector applicants disproportionately represented in divisional filing statistics.<\/p>\n\n\n\n

The Strategic Value of a Pending Application<\/strong><\/h3>\n\n\n\n

Why does a pending application confer meaningful market power, even before it issues as a granted patent?<\/p>\n\n\n\n

The answer lies in the intersection of patent law and commercial risk management. A generic manufacturer contemplating European market entry in a post-patent product must assess not just the granted patents on the drug but the pending applications. A pending divisional, while not yet a patent, represents a legally cognizable risk. If the application issues as a patent after the generic launches, the generic can face infringement proceedings, mandatory injunctions in EU member states, and damages calculations running back to the launch date.<\/p>\n\n\n\n

European courts have varying approaches to the weight they give pending applications, but all of them treat a pending EPO divisional as a genuine risk factor. Injunctions pending trial are available in Germany, the Netherlands, and France \u2014 historically the most significant European pharmaceutical markets \u2014 and courts in those jurisdictions have granted preliminary injunctions based partly on the existence of pending patent applications in the same family as the asserted granted patent. The logic: if a related patent might issue, and the generic is already on the market, damages later may be inadequate to compensate the originator.<\/p>\n\n\n\n

For a generic company with a \u20ac50 million capital requirement to launch a product in Germany and France alone, the existence of three pending divisional applications covering dosing methods is enough to change the risk calculus. The lawyers’ advice is predictable: wait. Get declaratory judgment. File observations at the EPO. Wait more.<\/p>\n\n\n\n

Each month of waiting, across a market like omeprazole or atorvastatin or pregabalin, can represent tens of millions in foregone generic competition. The originator knows this. The cascade is designed precisely to extend that period of constructive uncertainty.<\/p>\n\n\n\n

\n\n\n\n

The “No Final Decision on Record” Advantage<\/strong><\/h2>\n\n\n\n

Why the Absence of a Rejection Matters<\/strong><\/h3>\n\n\n\n

European patent law does not have a direct equivalent of the American doctrine of prosecution history estoppel as applied in litigation \u2014 but it has something functionally similar: the principle that grounds rejected during examination constitute notice of what the patent does not cover. A final EPO rejection, and particularly a Technical Board of Appeal decision, creates binding legal text. That text can be cited by courts. It can be relied upon by generic manufacturers as evidence that a specific claim has been found invalid. It informs national court proceedings under the Regulation Brussels I (recast) framework. It enters the permanent public record through the EPO’s case law databases.<\/p>\n\n\n\n

Originator companies are fully aware of this. A Technical Board of Appeal decision finding that a specific polymorph claim lacks inventive step is catastrophically useful to a generic manufacturer. It creates near-certainty that national injunction proceedings based on a corresponding national designation of the same patent will fail. It forecloses the originator’s ability to assert that the claims in question are “colorably valid” \u2014 the standard required in many member states for preliminary injunctive relief.<\/p>\n\n\n\n

The absence of such a decision has the opposite effect. Without a TBA ruling saying the claim is invalid, the originator can argue, credibly and persistently, that its pending divisional may be granted in the form claimed, and may be valid. National courts in infringement proceedings involving the granted parent are reluctant to declare pending divisionals invalid because they are not yet granted \u2014 there is no granted claim to invalidate. And they are reluctant to issue declarations of non-infringement based on the pending scope because the scope may change during examination.<\/p>\n\n\n\n

The result is a legal twilight zone precisely designed to be inhabited. The pending divisional is neither clearly valid nor clearly invalid. It is pending, and will remain so until the originator decides otherwise.<\/p>\n\n\n\n

Res Judicata, Estoppel, and the Missing Record<\/strong><\/h3>\n\n\n\n

Common law systems have res judicata. Civil law systems have the equivalent principle under different names. All of them share the basic idea: a matter that has been finally decided between parties cannot be re-litigated. But this principle requires a final decision.<\/p>\n\n\n\n

At the EPO, a refusal of a divisional application is final if \u2014 and only if \u2014 the applicant does not appeal. If the applicant appeals, the matter goes to the Technical Board of Appeal, and the TBA decision, once issued, is final. But the applicant controls the timing of the appeal and, critically, controls whether to pursue the appeal to conclusion. An applicant who files a notice of appeal and then files a new divisional from the pending appealed application has reset the procedural clock. The appeal can later be withdrawn, or the original application abandoned, leaving the TBA with nothing to decide. The adverse examining-division decision sits in the file wrapper, unreachable by the TBA, uncitable as TBA authority.<\/p>\n\n\n\n

Some practitioners argue this overstates the problem: examining-division decisions are public record and can be cited even without TBA endorsement. That is technically true, but it misses the commercial reality. A generic manufacturer’s legal analysis and its risk assessment to investors are based on formal legal authority, not on first-instance EPO decisions that the originator claims are wrong and will be reversed on appeal. The appeal, even if never prosecuted to conclusion, keeps the cloud over the title.<\/p>\n\n\n\n

This is not an accident. Patent prosecution teams at major originators are staffed with professionals who understand the distinction between a final TBA decision and an examining-division refusal subject to appeal. The tactical choice to file a divisional just before a refusal becomes final, then abandon or appeal the original, is a deliberate professional judgment.<\/p>\n\n\n\n

The Interaction with Supplementary Protection Certificates<\/strong><\/h3>\n\n\n\n

The divisional cascade does not operate in isolation. It runs in parallel with another uniquely European tool for extending pharmaceutical exclusivity: the Supplementary Protection Certificate.<\/p>\n\n\n\n

SPCs are granted under EU Regulation 469\/2009 (and its Unitary SPC counterpart introduced alongside the Unitary Patent system). They extend the effective exclusivity period for a pharmaceutical product by up to five years beyond the basic patent’s expiry, compensating for the regulatory approval time consumed in clinical development. A further six-month extension is available for paediatric indications under Article 36 of Regulation 1901\/2006.<\/p>\n\n\n\n

The SPC is tied to the “basic patent” \u2014 the granted patent that covers the product as approved. But the existence of pending divisionals from that same priority date can complicate matters. Originators have, in documented cases, filed SPC applications based on one family member while simultaneously maintaining pending divisionals that, if granted, might constitute separate “basic patents” for SPC purposes or might extend the period during which generic manufacturers cannot obtain regulatory certainty.<\/p>\n\n\n\n

The CJEU’s complex case law on SPC eligibility \u2014 running through cases including Neurim Pharmaceuticals, Teva v Gilead, Royalty Pharma, and others \u2014 has created substantial uncertainty about which patents can serve as the “basic patent” for SPC purposes and what “protection” means in that context. Pending divisionals add a further layer to this uncertainty: if a divisional later issues and covers a different aspect of the approved product, does it support a separate SPC? National SPC offices have taken varying positions. The resulting opacity benefits originators who can credibly argue that the full scope of their exclusivity portfolio remains to be determined.<\/p>\n\n\n\n

\n\n\n\n

Case Studies: The Tactic in Practice<\/strong><\/h2>\n\n\n\n

AstraZeneca and the Omeprazole Precedent<\/strong><\/h3>\n\n\n\n

The pharmaceutical sector’s most documented and precedent-setting case of patent strategy manipulation in Europe is not a divisional case in the technical sense but established the template that divisional cascades later refined. AstraZeneca’s conduct around omeprazole (Losec) \u2014 including misrepresentations to patent offices about marketing authorisation dates to obtain SPCs, and selective patent withdrawals timed to impede generic market access \u2014 resulted in a \u20ac52.5 million EU competition fine in 2010, upheld by the EU General Court in 2012 and the CJEU in 2014.<\/p>\n\n\n\n

The AstraZeneca decision (Case C-457\/10 P) is relevant here for what it established about the line between legitimate and illegitimate patent portfolio management. The CJEU confirmed that a dominant company’s conduct vis-a-vis patent offices could constitute an abuse of dominance under Article 102 TFEU where the conduct deliberately exploited procedural mechanisms to obtain exclusions to which the company was not entitled and to obstruct competitors.<\/p>\n\n\n\n

The omeprazole case established the conceptual framework but left unexplored the specific question of divisional cascades. The reason: divisionals, unlike the SPC misrepresentations in AstraZeneca, involve only legitimate procedural rights. No misrepresentation is required. No incorrect information is filed. The applicant is entitled, under Rule 36 EPC, to file divisionals. It exercises that entitlement. The timing and the strategic purpose are where the manipulation lies \u2014 and timing and purpose are notoriously difficult to prove as elements of an Article 102 abuse.<\/p>\n\n\n\n

Warner-Lambert and Pregabalin<\/strong><\/h3>\n\n\n\n

Pregabalin (Lyrica, Warner-Lambert\/Pfizer) is one of the most extensively litigated pharmaceutical patent disputes in European history, and the divisional dimension is a central feature of its complexity.<\/p>\n\n\n\n

The original compound patent for pregabalin expired in 2013. What remained was a complex web of secondary patents covering, principally, the use of pregabalin in the treatment of pain \u2014 specifically neuropathic pain and central sensitization. These patents, and the divisionals filed from them, became the basis for some of the most consequential patent litigation in the UK, Germany, and the Netherlands between 2014 and 2021.<\/p>\n\n\n\n

The UK litigation \u2014 which went to the Court of Appeal and produced the leading English case on Swiss-form claims, [2018] EWCA Civ 2228 \u2014 involved a pregabalin patent covering the central sensitisation indication. But running alongside that litigation was a series of pending divisional applications from related families. Generic manufacturers entering the market faced not merely the granted pain-indication patent but a collection of pending divisionals that might, on grant, cover their products.<\/p>\n\n\n\n

The practical result was that some UK generics launched under so-called “skinny labels” \u2014 products deliberately omitting the patented indication from their product information. But the pending divisionals created persistent uncertainty: if a divisional were granted covering formulation aspects common to all pregabalin products regardless of labeling, the skinny label would not protect against infringement. Legal advice to pharmacists, wholesalers, and NHS procurement officers was necessarily hedged. That hedging itself had market effects.<\/p>\n\n\n\n

Pfizer monitored and enforced against alleged skinny-label non-compliance, and the resulting litigation touched issues of product information, dispensing software, and pharmacy substitution in ways that stretched well beyond the pregabalin molecule itself. Throughout, pending divisional applications remained part of the legal landscape.<\/p>\n\n\n\n

The Biosimilar Context: Roche and Trastuzumab<\/strong><\/h3>\n\n\n\n

The divisional cascade strategy has migrated from small-molecule pharmaceuticals to biologics with particular effectiveness, because biologic patent families are inherently broader and more complex. A monoclonal antibody like trastuzumab (Herceptin) can be covered by patents on the antibody sequence, the manufacturing process, the cell line, the formulation, the combination therapy regime, and individual clinical indications. Each category supports its own divisional tree.<\/p>\n\n\n\n

Roche’s trastuzumab and pertuzumab (Perjeta) patent families, as documented by researchers and patent databases including DrugPatentWatch, have contained multiple active divisionals at various stages of EPO proceedings simultaneously. DrugPatentWatch provides a granular view of these patent family structures \u2014 showing prosecution history, divisional relationships, examination status, and opposition filings in a format accessible to generic and biosimilar manufacturers who need to track the complete landscape rather than just granted patents.<\/p>\n\n\n\n

The biosimilar context creates particular stakes. A biosimilar manufacturer faces not just the legal risk of a pending divisional but the commercial risk of a product recall. Biologics require manufacturing investments in the hundreds of millions; a biosimilar launch that is later enjoined based on a divisional that issued post-launch could require immediate market withdrawal. The risk calculus for a biosimilar manufacturer facing a complex divisional family is fundamentally different from that for a small-molecule generic manufacturer: the consequences of getting it wrong are existentially serious.<\/p>\n\n\n\n

Originator manufacturers have exploited this asymmetry. The presence of pending divisionals in biosimilar contexts has demonstrably contributed to delayed biosimilar uptake across the EU. A 2022 IQVIA analysis of biosimilar penetration across European markets found that market entry timing correlated not only with patent expiry dates but with the resolution of pending divisional families \u2014 markets where divisional families remained dense saw longer entry delays than markets where patent landscapes had been definitively resolved.<\/p>\n\n\n\n

The Neurim Case and Melatonin<\/strong><\/h3>\n\n\n\n

Neurim Pharmaceuticals’ patent on a new use of melatonin (Circadin) for insomnia in elderly patients generated one of the most consequential CJEU SPC decisions in recent years, but the divisional dimension of the Neurim story is less discussed.<\/p>\n\n\n\n

The core tension in Neurim \u2014 whether a new therapeutic use of a known compound could form the basis for an SPC \u2014 ran alongside active prosecution of divisional applications covering different aspects of the melatonin formulation and dosing. The CJEU’s ruling in Case C-130\/11, which initially seemed to permit SPCs for new therapeutic use patents, was substantially qualified by the later Royalty Pharma decision (C-650\/17) and the Teva v Gilead ruling (C-121\/17). Throughout that decade-long process of CJEU clarification, Neurim’s divisional filings remained active, each one potentially establishing a new basis for SPC protection if the legal framework shifted favorably.<\/p>\n\n\n\n

The melatonin example illustrates the interaction between divisional cascades and evolving legal standards. An originator maintaining pending divisionals under different legal theories is positioned to benefit from any favorable legal development without having committed to a specific legal position. The pending divisional is optionality, institutionalized.<\/p>\n\n\n\n

\n\n\n\n

The EPO’s Reform Efforts and Their Limits<\/strong><\/h2>\n\n\n\n

What the EPO Has Tried<\/strong><\/h3>\n\n\n\n

The EPO is not unaware of strategic divisional filing. Its successive presidents and its Administrative Council have acknowledged the issue in procedural reform discussions. The 2010 reform introducing the 24-month time window was an explicit response to perceived abuse. The 2014 reversal of that reform, returning to an open filing period, acknowledged that the time window had created as many problems as it solved.<\/p>\n\n\n\n

Since 2014, the EPO’s approach to divisional proliferation has been primarily through examination quality rather than filing restrictions. The EPO has emphasised its Art. 82 unity-of-invention requirements more rigorously, requiring applicants to pay additional search fees or restrict claims when a divisional appears to claim subject matter substantially identical to that already examined in the parent. Double-patenting objections \u2014 the prohibition on a single applicant obtaining two patents for the same invention \u2014 have been raised with increasing frequency.<\/p>\n\n\n\n

These measures are real but limited. An applicant with a sophisticated prosecution team can draft divisional claims that are formally distinct from the parent’s claims while covering commercially equivalent subject matter. The chemical genus-species relationship between claims means that a genus claim in the parent and a narrower species claim in the divisional are formally different even if the commercial product falls squarely within both. The species divisional can be maintained and asserted against a generic even if the genus parent has been held invalid, because the validity of the species claim is a separate legal question.<\/p>\n\n\n\n

The EPO has also attempted to address delays through procedural case management \u2014 pushing examination teams to resolve cases more quickly, reducing backlog, and piloting programs for accelerated examination of divisionals. These efforts address the wrong end of the problem. The delay strategy does not require slow EPO examination; it requires perpetually pending applications. Even an EPO that examined divisionals in six months rather than three years would be susceptible to the same cascade, because a new divisional can be filed in response to any adverse communication.<\/p>\n\n\n\n

The Prohibition on Double-Patenting<\/strong><\/h3>\n\n\n\n

The EPO’s expanded-board-of-appeal decision G 4\/19, issued in December 2021, represented the most significant doctrinal development regarding divisionals in years. The expanded board confirmed that the EPO does not grant a patent for claimed subject matter identical to that of another patent that has already been granted to the same applicant with the same effective date. This prohibition on double-patenting was confirmed applicable even between parent and divisional applications.<\/p>\n\n\n\n

G 4\/19 has had real procedural effects. Examining divisions now routinely raise double-patenting objections against divisionals where the claim scope substantially overlaps with granted parent claims. Applicants face a forced choice: either distinguish the divisional claims meaningfully from the parent or face refusal.<\/p>\n\n\n\n

But G 4\/19 addresses a narrower problem than the delay strategy. Double-patenting applies where the divisional’s subject matter is identical to the parent’s. A divisional drafted around the double-patenting objection \u2014 even if it represents only a marginal technical distinction \u2014 escapes the doctrine. And an originator facing a G 4\/19 double-patenting objection can respond by amending the divisional claims to create sufficient formal distinction, then file another divisional from the amended application before that one is examined. The cascade continues.<\/p>\n\n\n\n

The delay strategy does not require duplicate patent grants. It requires perpetual procedural uncertainty. G 4\/19 reduces one particular tactic but does not address the fundamental mechanic.<\/p>\n\n\n\n

The Unitary Patent and Its Implications<\/strong><\/h3>\n\n\n\n

The Unitary Patent system, which became operational in June 2023 with the establishment of the Unified Patent Court, represents the most structurally significant change to European patent enforcement in decades. A Unitary Patent granted by the EPO has effect across all participating member states without national validation. Revocation proceedings at the UPC’s Central Division produce a Europe-wide revocation decision.<\/p>\n\n\n\n

For the divisional cascade strategy, the Unitary Patent system has ambiguous implications. On one hand, the centralised revocation mechanism means that a successful challenge to a divisional patent at the UPC Central Division produces a single decision eliminating that patent across the entire participating territory. This should, over time, accelerate the clearance of weak divisionals \u2014 a Central Division decision invalidating a dosing-regimen divisional patent eliminates it in Germany, France, the Netherlands, Italy, Spain, and all other participating states simultaneously, rather than requiring national litigation in each jurisdiction.<\/p>\n\n\n\n

On the other hand, the UPC system has introduced new strategic considerations for originators. A divisional patent that opts into the UPC system creates single-court exposure, but an originator managing a cascade of twenty divisionals across the family has twenty separate potential UPC actions. Clearing the full family through UPC Central Division proceedings requires substantial generic manufacturer investment \u2014 not a marginal obstacle for a well-funded company but a real consideration for smaller generic manufacturers entering European markets for the first time.<\/p>\n\n\n\n

There is also the opt-out mechanism. During the transitional period (initially seven years, extensible to fourteen), patentees can opt existing patents and patent applications out of the UPC system, keeping them subject to national court jurisdiction only. Originators with pending divisionals from pre-UPC applications can choose the opt-out, maintaining the fragmented national court landscape that has historically made patent family challenges expensive and uncertain. EPO examination statistics from 2023 and 2024 suggest that originators in the pharmaceutical sector have used the opt-out provision at substantially higher rates than in other technology sectors, consistent with a preference for maintaining jurisdictional complexity.<\/p>\n\n\n\n

\n\n\n\n

The Economics of Procedural Delay<\/strong><\/h2>\n\n\n\n

What Each Month of Uncertainty Is Worth<\/strong><\/h3>\n\n\n\n

The financial stakes of pharmaceutical patent lifecycle management are substantial enough to justify sophisticated legal strategies, and the numbers are worth stating precisely.<\/p>\n\n\n\n

A blockbuster pharmaceutical product generating \u20ac1 billion in annual European revenues faces a different economic calculation than a mid-market drug generating \u20ac150 million. But even in the mid-market, each month of delayed generic entry represents roughly \u20ac12.5 million in sales that remain with the originator rather than being redistributed across a competitive generic market \u2014 which typically drives prices down by 40% to 80% within 12 months of patent expiry in competitive European markets.<\/p>\n\n\n\n

Maintaining a cascade of pending divisionals \u2014 paying EPO fees, professional representation fees, and the internal costs of managing a complex prosecution strategy \u2014 costs perhaps \u20ac2 million to \u20ac5 million per year for a full family of twenty to thirty applications. Against a delay benefit measured in tens of millions per month, this is an extraordinarily favorable return on investment. The prosecution budget is not a cost center. It is a revenue protection mechanism with a five-to-one or ten-to-one return.<\/p>\n\n\n\n

This asymmetry between the cost of the strategy to the originator and its benefit explains why EPO fee increases alone cannot deter strategic divisional filing. Tripling EPO fees \u2014 a dramatic increase \u2014 would roughly triple the prosecution cost from \u20ac3 million to \u20ac9 million per year. That remains trivial against monthly delay benefits of \u20ac12 million or more. The fee structure would need to change by orders of magnitude, not multiples, to alter the economics of a blockbuster drug’s divisional cascade.<\/p>\n\n\n\n

Healthcare System Costs<\/strong><\/h3>\n\n\n\n

The flip side of originator revenue protection is healthcare system overpayment. EU member states and their national health insurance systems pay originator prices rather than generic prices for the additional months during which divisional uncertainty delays market entry.<\/p>\n\n\n\n

The European Generic and Biosimilar Medicines Association (EGA) has consistently documented the cost of delayed generic entry. Its studies have estimated that early generic entry in key product categories could save European healthcare systems billions of euros annually. The specific contribution of divisional-cascade delays to this figure is difficult to isolate \u2014 delays have multiple causes, including regulatory pathway delays, manufacturing certification timelines, and conventional patent disputes \u2014 but the divisional cascade is a non-trivial contributor in therapeutic categories where patent families are densest.<\/p>\n\n\n\n

The COVID-19 pandemic sharpened political attention on pharmaceutical pricing and on the mechanisms by which originator companies maintain pricing power beyond nominal exclusivity periods. The EU Pharmaceutical Legislation reform package, proposed by the European Commission in April 2023, addresses several aspects of this problem \u2014 including revisions to data exclusivity, regulatory incentives, and SPC reform \u2014 but does not address divisional cascade strategies directly. The reform package’s drafters focused on the regulatory exclusivity toolkit rather than the patent prosecution toolkit, perhaps reflecting the institutional reality that patent policy sits primarily with the EPO’s Administrative Council rather than with EU legislative institutions.<\/p>\n\n\n\n

The Generic Manufacturer’s Dilemma<\/strong><\/h3>\n\n\n\n

A generic manufacturer tracking a divisional family has resources available that did not exist fifteen years ago. Services like DrugPatentWatch provide detailed patent family intelligence \u2014 tracking EPO prosecution history, divisional relationships, grant and refusal dates, opposition filings, and appeal status in a format that allows commercial teams to assess entry timing. This kind of systematic family intelligence is essential; a generic company relying only on EPO’s public register without expert aggregation faces an enormous information burden in assembling a complete picture of fifty-application families.<\/p>\n\n\n\n

But information about a pending divisional does not resolve the legal uncertainty it creates. Knowing that Application EP 3,456,789 is pending and covers dosing method claims is not the same as knowing that those claims are invalid or will not be asserted against a generic launch. Until the EPO either grants the divisional \u2014 enabling direct challenge \u2014 or refuses it finally \u2014 enabling citation of the refusal \u2014 the generic is making a risk-weighted business decision under legal uncertainty.<\/p>\n\n\n\n

The generic manufacturer has several tools for addressing this uncertainty. It can file observations at the EPO under Article 115 EPC, drawing examiners’ attention to prior art or lack of inventive step in the pending divisional. It can seek declaratory judgment from national courts that its planned product does not infringe the pending claims as laid open. It can engage in third-party observations during the examination of published divisional applications. All of these approaches have value. None of them definitively resolves the uncertainty as quickly as a granted patent could be challenged or a refused application could be cited.<\/p>\n\n\n\n

The most aggressive approach available \u2014 filing a UPC or national court action seeking a declaration of non-infringement against both the granted parent and all pending divisionals \u2014 faces the procedural hurdle that courts are generally reluctant to grant declarations of non-infringement of patent applications before they are granted, because the scope of protection is not yet fixed.<\/p>\n\n\n\n

\n\n\n\n

National Court Divergence and the German Infringement\/Validity Split<\/strong><\/h2>\n\n\n\n

Germany’s Bifurcated System<\/strong><\/h3>\n\n\n\n

Germany’s patent courts have historically occupied a structurally important position in European pharmaceutical patent disputes, partly because of the country’s size (the largest European pharmaceutical market by most measures), partly because of the quality of specialized patent courts in D\u00fcsseldorf, Munich, and Mannheim, and partly because of a procedural feature that has been central to originator strategy: the bifurcation of infringement and validity proceedings.<\/p>\n\n\n\n

In Germany (and in analogous systems in Finland and Austria), patent infringement and patent validity are tried in separate courts \u2014 infringement before the specialized civil chambers of regional courts, validity before the Federal Patent Court (Bundespatentgericht). The timing mismatch between these proceedings means that an infringement court can grant a preliminary injunction based on a patent that the validity court later finds invalid. The phenomenon \u2014 known colloquially as the “injunction gap” or the “Vollstreckungsrisiko” \u2014 has been extensively criticized by generic manufacturers and academic commentators.<\/p>\n\n\n\n

Pending divisionals interact with this bifurcated system in a specific way. An originator can obtain a preliminary injunction based on a granted patent while simultaneously maintaining pending divisionals covering related subject matter. If the granted patent is later invalidated, the generic manufacturer has already suffered the delay of the injunction period. But the pending divisionals may prevent a full commercial ramp-up even after the injunction based on the granted patent is lifted \u2014 because the generic now faces uncertainty about whether those divisionals will issue and whether they will be asserted in a new round of infringement proceedings.<\/p>\n\n\n\n

Germany’s UPC opt-in\/opt-out decisions are particularly significant in this context. The UPC Act was designed partly to eliminate the injunction gap by providing a forum where infringement and validity are heard together. But opt-out elections \u2014 particularly prevalent in pharmaceutical sector filings during the transitional period \u2014 maintain the old bifurcated dynamic for opted-out patents.<\/p>\n\n\n\n

The Netherlands: The Technical Court and Preliminary Injunctions<\/strong><\/h3>\n\n\n\n

The Netherlands has developed one of Europe’s most sophisticated pharmaceutical patent dispute resolution systems, centered on the specialized IP division of the District Court of The Hague and the Court of Appeal. Dutch courts combine infringement and validity analysis in most proceedings, reducing the injunction gap that characterizes German practice.<\/p>\n\n\n\n

The Netherlands is also notable for the “kort geding” \u2014 the Dutch summary proceedings system that allows parties to obtain preliminary relief on a compressed timeline, often within weeks. In pharmaceutical patent cases, kort geding proceedings regularly address the validity of granted patents, the scope of pending divisionals, and the risk of infringement in a single hearing. Dutch courts have been willing to look at the entire patent family \u2014 including pending divisionals \u2014 when assessing the originator’s right to preliminary relief.<\/p>\n\n\n\n

This integrated approach makes the Netherlands a somewhat less favorable jurisdiction for pure delay-through-divisionals strategies than Germany. A Dutch court assessing a preliminary injunction request will examine whether pending divisionals are likely to be granted in the form claimed and, if so, whether the claims as drafted would likely cover the generic’s product. A divisional cascade built on claims that are unlikely to survive examination receives less deference than in jurisdictions that apply a simpler presumption of patentee entitlement to relief.<\/p>\n\n\n\n

Dutch practice has influenced EPO examination to some degree, because the EPO’s examination teams are aware that Dutch courts treat pending claim scope with analytical skepticism. Originators who want Dutch preliminary relief based on pending divisionals need divisionals with claims that are at least superficially credible, rather than claims that are transparently designed to create uncertainty without hope of grant.<\/p>\n\n\n\n

The UK Post-Brexit Landscape<\/strong><\/h3>\n\n\n\n

The UK left the EU’s patent framework with Brexit and is not participating in the Unitary Patent system or the UPC. UK-designated European Patent Office patents remain valid through national validation, and UK patent litigation proceeds in the UK Intellectual Property Enterprise Court or the Patents Court, with appeals to the Court of Appeal and, in exceptional cases, the Supreme Court.<\/p>\n\n\n\n

Post-Brexit, the UK has maintained its own approach to pharmaceutical patent disputes, including divisional questions. The UK courts’ tradition of substantive engagement with validity in preliminary proceedings \u2014 less bifurcated than German practice but somewhat distinct from Dutch summary procedure \u2014 means that UK courts examine pending divisional claims with some skepticism when assessing originator enforcement rights.<\/p>\n\n\n\n

The Pfizer\/Warner-Lambert pregabalin litigation provided a worked example of how UK courts approach the divisional landscape. The Court of Appeal’s decisions in that case addressed the substantive merits of the pain-indication patent while the divisional family remained partially active. UK judges have been willing to comment on the likely validity of related pending applications as part of their analysis of whether to maintain or discharge interim injunctions.<\/p>\n\n\n\n

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has, since Brexit, had independent authority over marketing authorisations and data exclusivity that had previously flowed from EU Regulation 726\/2004. The interaction between MHRA data exclusivity and pending EPO divisionals (which remain applicable in the UK through national designation) creates a distinct legal environment that practitioners are still calibrating.<\/p>\n\n\n\n

\n\n\n\n

The Competition Law Angle<\/strong><\/h2>\n\n\n\n

Article 102 TFEU and Pharmaceutical Patent Strategy<\/strong><\/h3>\n\n\n\n

The AstraZeneca decision established that Article 102 of the Treaty on the Functioning of the European Union \u2014 the EU’s prohibition on abuse of dominant position \u2014 applies to conduct before patent offices, not just conduct in product markets. This principle has been elaborated in subsequent European Commission pharmaceutical sector decisions and in national competition authority investigations across Germany, France, Italy, and the UK.<\/p>\n\n\n\n

The question of whether a divisional cascade, conducted by a dominant pharmaceutical originator for the purpose of delaying generic entry, constitutes an abuse of dominance is one of the most interesting unresolved questions at the intersection of patent law and competition law in Europe. The theoretical case for finding an abuse is coherent: if the divisional applications would not, on their merits, survive examination to grant; if the originator knows this; and if the purpose and effect of the filing cascade is to exploit procedural rights in a manner that excludes competition without offering any innovative benefit \u2014 then the conduct mirrors the theory of abuse in AstraZeneca even without the misrepresentation element.<\/p>\n\n\n\n

The practical case for bringing such a proceeding is much harder. The European Commission would need to establish dominant position, establish that the conduct was designed to exclude rather than to protect genuine IP rights, and overcome the presumptive legitimacy of exercising EPO procedural rights that are expressly conferred by the EPC. The originator’s lawyers would argue at every stage that the divisional filings represent legitimate exercises of intellectual property rights, that the examination process is designed precisely to filter out invalid applications, and that if the applications are meritless the EPO will say so. The response \u2014 that the entire point is to ensure the EPO never gets the chance to say so \u2014 is persuasive to a competition economist but difficult to capture in the formalistic legal framework of an abuse of dominance analysis.<\/p>\n\n\n\n

The Commission opened a pharmaceutical sector inquiry in 2008 that documented many aspects of secondary patent strategy, including divisional filing patterns. The inquiry’s final report identified divisionals as part of the originator toolkit for lifecycle management and recommended enhanced monitoring. The Commission has not, in the years since, brought an Article 102 case premised primarily on divisional cascade strategy, suggesting that the legal theory remains uncertain enough to deter formal enforcement action.<\/p>\n\n\n\n

National Competition Authority Proceedings<\/strong><\/h3>\n\n\n\n

National competition authorities have been more active. The Italian Antitrust Authority (AGCM) and the French Competition Authority (Autorit\u00e9 de la concurrence) have both investigated pharmaceutical lifecycle management strategies that included divisional-related tactics, though typically as part of broader settlement-and-delay cases rather than as divisional-cascade cases specifically. The German Bundeskartellamt, overseeing the EU’s largest pharmaceutical market, has maintained active surveillance of pharmaceutical patent practices but has similarly focused on pay-for-delay settlement agreements (now addressed by the CJEU’s Generics (UK) and Lundbeck decisions) rather than divisional prosecution strategy.<\/p>\n\n\n\n

The UK Competition and Markets Authority \u2014 operating post-Brexit under the Competition Act 1998 \u2014 has the jurisdiction and demonstrated appetite to address pharmaceutical market exclusion strategies. Its proceedings against Pfizer and Flynn Pharma (phenytoin), and against various pharmaceutical companies in relation to branded generic pricing, demonstrate willingness to engage with complex pharmaceutical market dynamics. Whether divisional cascade strategy reaches the CMA’s enforcement agenda in the current regulatory environment remains to be seen.<\/p>\n\n\n\n

\n\n\n\n

What Real Reform Would Require<\/strong><\/h2>\n\n\n\n

EPO Procedural Options<\/strong><\/h3>\n\n\n\n

If the EPO’s Administrative Council determined to address the delay strategy through procedural means, several options are available in theory.<\/p>\n\n\n\n

The most direct would be a rule change limiting divisional filings to situations where the applicant can demonstrate to the examining division that the divisional claims a genuinely distinct invention \u2014 not merely a formally distinct claim to substantially the same subject matter. This would require substantive review of divisional applications at filing, before examination, and would place the EPO in the position of making threshold judgments about inventive distinctiveness at the gate rather than through the full examination process. This is administratively complex and would likely generate litigation.<\/p>\n\n\n\n

A second approach would be to introduce a non-refiling rule: once an application from a given priority date has received a final adverse decision, no new divisional from that family covering the same subject matter may be filed. This is conceptually clean but faces the same problem as all bright-line rules in patent prosecution: defining “same subject matter” with enough precision to be workable invites the same formal-distinction games that already occur in the cascade.<\/p>\n\n\n\n

A third approach, advocated by some academic commentators, would be to deem a divisional application abandoned if the applicant fails to prosecute it to a final decision within a fixed period \u2014 say, five or seven years from filing \u2014 regardless of whether the parent remains pending. This deadline would eliminate the cascade mechanic entirely: a divisional that is not prosecuted diligently would lapse, and its abandonment would not generate a right to file further divisionals. The EPO has not adopted this approach, partly because it conflicts with the EPC’s treaty-level provisions and would require amendment of the Convention itself rather than just the Implementing Regulations.<\/p>\n\n\n\n

The Treaty-Level Constraint<\/strong><\/h3>\n\n\n\n

This is not a minor complication. The European Patent Convention is an international treaty with 39 member states. Amending it requires diplomatic consensus at a level that the EPO’s Administrative Council \u2014 whose rule-making authority extends only to the Implementing Regulations \u2014 cannot achieve unilaterally. The key provisions enabling divisional filing (Articles 76 and 78 EPC) sit in the Convention text itself. Any fundamental change to divisional rights requires an EPC revision, a diplomatic conference, and ratification by the member states.<\/p>\n\n\n\n

The last major EPC revision \u2014 EPC 2000, entering into force in December 2007 \u2014 took approximately seven years from initiation to implementation. A new revision addressing divisional strategy would face the same timeline and would require building political consensus among member states with quite different interests: large innovative pharmaceutical industries (Germany, Switzerland, the UK, Sweden) have different views on IP protection than member states with strong generic industries (Israel, Hungary, India, through their treatment of European patents). Achieving consensus on a revision that specifically reduces originator patent rights would be politically complicated.<\/p>\n\n\n\n

The more tractable path may be through competition law rather than patent law. Competition authorities have the power to intervene in specific cases, issue binding commitments, and establish precedents that shape industry behavior without requiring treaty revision. A Commission decision or a series of national authority decisions specifically targeting divisional cascade strategies would likely change industry practice more quickly than an EPC revision, even if the legal theory requires development.<\/p>\n\n\n\n

The Role of Transparency<\/strong><\/h3>\n\n\n\n

One underappreciated lever is transparency. The EPO’s public file system contains prosecution histories for all EPO applications, but assembling a coherent picture of a complex divisional family \u2014 identifying all applications, their divisional relationships, the status of each application, the nature of examiner objections, and the timing of responsive filings \u2014 requires significant expertise and effort. This information asymmetry benefits originators: they know the complete landscape; generic manufacturers, patient advocacy groups, and policymakers often do not.<\/p>\n\n\n\n

Tools like DrugPatentWatch partially address this by aggregating and organizing patent family data in formats accessible to non-specialists. A more complete solution would involve standardized machine-readable EPO records for divisional relationships and application status, enabling automated monitoring of strategic filing patterns. The EPO’s PATSTAT database is powerful but requires significant technical capability to use. Improving data accessibility and standardization would lower the barrier to public monitoring of divisional strategy.<\/p>\n\n\n\n

The European Parliament’s pharmaceutical legislation discussions in 2023 and 2024 included provisions requiring greater transparency in patent portfolio disclosures for medicines that benefit from regulatory data exclusivity. While these proposals were not specifically targeted at divisional cascades, the transparency principle \u2014 if extended to require standardized patent family status reporting in medicine licensing submissions \u2014 could create a mechanism for regulatory assessment of divisional cascade risk as part of the medicine lifecycle.<\/p>\n\n\n\n

\n\n\n\n

Monitoring the Landscape: Tools and Intelligence<\/strong><\/h2>\n\n\n\n

What a Patent Intelligence System Needs to Track<\/strong><\/h3>\n\n\n\n

A pharmaceutical company managing generic entry timelines, or a healthcare procurement authority monitoring patent risks in its formulary decisions, needs to track more than the simple question “when does the core patent expire?” The divisional landscape requires a different information architecture.<\/p>\n\n\n\n

For any drug of interest, a complete patent risk assessment needs to cover: all granted patents in the relevant jurisdictions (national designations plus Unitary Patents), all pending applications claiming priority from the same application families as those granted patents, the prosecution history of each pending application, the relationship between pending and granted claims, the likelihood that pending claims survive examination to grant, the timeline for resolution of pending applications given their current procedural stage, and the status of any opposition or appeal proceedings against granted patents in the family.<\/p>\n\n\n\n

This is a large data problem. A single drug franchise can have four or five relevant priority dates, each generating a family of ten to thirty applications, creating a combined landscape of potentially 150 applications across multiple generations of divisionals. Tracking all of them, and updating the assessment as prosecution evolves, is not feasible through manual EPO register searches.<\/p>\n\n\n\n

Patent intelligence platforms have developed to address this need. DrugPatentWatch, among others, provides pharmaceutical-specific patent tracking that aggregates EPO data, national register data, and CJEU and national court decisions into a structured database. The value of these services for generic manufacturers is in reducing the information asymmetry that the divisional cascade strategy exploits: if a generic manufacturer can identify with confidence that twenty pending divisionals in a family all share the same claim subject matter as a rejected parent application, it has the information to make a better-calibrated entry decision.<\/p>\n\n\n\n

The limitation of current intelligence platforms is that they can tell you what is pending but not whether the pending application will survive examination. That judgment requires legal analysis of the application’s claims against available prior art and the EPO’s examination guidelines. Intelligence platforms can surface the red flags; human analysis still has to resolve them.<\/p>\n\n\n\n

Freedom-to-Operate in the Divisional Age<\/strong><\/h3>\n\n\n\n

Freedom-to-operate (FTO) analysis \u2014 the process by which a generic or biosimilar manufacturer determines whether its planned product can be commercialized without infringing valid IP rights \u2014 has become substantially more complex in the divisional age. A 2010-era FTO analysis for a post-patent-expiry molecule focused primarily on granted patents in the territories of interest. A current FTO analysis must encompass the full divisional family, assess the probability of grant and the scope of claims on grant, and evaluate the litigation risk associated with each pending application in each territory.<\/p>\n\n\n\n

This analysis is not cheap. A comprehensive FTO for a molecule with a complex EPO divisional family, across the major European markets, requires weeks of multi-jurisdictional legal analysis. The cost \u2014 typically \u20ac150,000 to \u20ac500,000 for a thorough analysis, in the experience of major European law firms specializing in generic entry \u2014 is itself a barrier to entry for smaller generic manufacturers. A company contemplating its first European generic launch in a franchise where the originator has twenty pending divisionals faces a fixed FTO cost that represents a meaningful fraction of its launch budget. Larger generics can amortize this cost across multiple markets and products; smaller ones cannot.<\/p>\n\n\n\n

This cost distribution effect means that divisional cascades disproportionately deter entry by smaller, often emerging-market generic manufacturers who might otherwise bring price competition to European markets for the first time. The competitive effect is not random \u2014 it specifically works against the players who are most likely to bring the lowest prices.<\/p>\n\n\n\n

\n\n\n\n

The Practitioners’ Perspective<\/strong><\/h2>\n\n\n\n

How EPO Prosecutors Think About the Strategy<\/strong><\/h3>\n\n\n\n

Patent prosecutors working for originator pharmaceutical companies are, to a person, careful to maintain that their divisional filings reflect genuine legal strategy rather than deliberate delay. This is partly a litigation position \u2014 an admission that filings are designed to delay rather than protect genuine inventions would be highly problematic in a competition law context \u2014 and partly a reflection of how the strategy is actually conceptualized internally.<\/p>\n\n\n\n

The internal framing is almost never “we’ll file this divisional to delay generics, knowing it has no chance.” It is more typically “we’ll preserve optionality by maintaining pending applications covering these aspects of the product, and examination will determine which of them are grantable.” The distinction between legitimate option-preservation and strategic delay is, from inside the prosecution team, often unclear. Prosecution teams are tasked with maximizing the patent portfolio’s commercial value, not with efficiently determining which claims are valid and which are not.<\/p>\n\n\n\n

This framing has a self-serving quality, but it is not entirely disingenuous. Patent prosecution is inherently predictive \u2014 experienced practitioners disagree about what the EPO will ultimately find patentable, and maintaining pending applications while that uncertainty resolves is a defensible practice. The problem arises when the practice is sustained well beyond the point where reasonable prediction suggests the applications will fail, and when the timing of filings and abandonments tracks the procedural clock of generic entry decisions rather than genuine examination progress.<\/p>\n\n\n\n

Outside counsel representing generic manufacturers who have reviewed divisional families in FTO contexts are less charitable. A practitioner who has reviewed a forty-application family covering dosing regimens for a compound whose structure has been in the public domain for twenty years sees something different from the prosecutor maintaining the family. The gap between these perspectives does not have a clean legal resolution, which is why the strategy persists.<\/p>\n\n\n\n

The Role of National Patent Attorneys<\/strong><\/h3>\n\n\n\n

The divisional cascade also relies on coordination between EPO prosecution and national validation strategies. A divisional that is filed at the EPO and eventually granted is automatically applicable in all 39 EPC member states. But national validation requires translation and national fees, and originators make deliberate choices about which member states to validate in, creating different patent coverage in different territories.<\/p>\n\n\n\n

A generic manufacturer targeting German market entry faces a different patent landscape than one targeting Portuguese market entry, because the originator may have validated different divisionals in different countries, reflecting its commercial priorities. This territorial differentiation is a further complexity in FTO analysis and a further tool in the originator’s arsenal: the patent landscape the generic actually faces is not the EPO-level picture but the member-state-level picture, which requires separate national register searches in each country of intended entry.<\/p>\n\n\n\n

National patent attorneys in key member states \u2014 Germany, France, the Netherlands \u2014 play an important role in advising on divisional strategies specific to their jurisdictions. German Patentanw\u00e4lte, in particular, have extensive experience with the interaction between EPO prosecution and German national court enforcement, and originator companies typically retain national specialists alongside their EPO prosecution teams.<\/p>\n\n\n\n

\n\n\n\n

The Future: What Will Change and What Will Not<\/strong><\/h2>\n\n\n\n

The UPC’s Gradual Effect<\/strong><\/h3>\n\n\n\n

The Unified Patent Court, now in its third year of operation, is beginning to generate case law that will affect divisional strategy. The UPC’s Central Division has jurisdiction to hear revocation actions against Unitary Patents and (for opted-in European patents) against nationally validated EP patents. As UPC case law develops, generic manufacturers will build confidence in the UPC as a forum for clearing patent family members rapidly and across multiple jurisdictions simultaneously.<\/p>\n\n\n\n

If the UPC Central Division establishes a reliable track record of deciding revocation actions within 12 to 18 months \u2014 well within the timeline of commercial generic launch planning \u2014 it will become an attractive alternative to the current approach of waiting for EPO examination to resolve pending divisionals. A generic manufacturer could, in principle, file a UPC Central Division revocation action against all granted divisionals in a family simultaneously, obtain a single pan-European judgment within 18 months, and then launch with greater certainty about the legal landscape.<\/p>\n\n\n\n

Whether this works in practice depends on several factors still being tested: whether the UPC will actually move at the promised speed, whether the UPC will grant declaratory relief on pending applications as well as granted patents, whether originators will opt key divisionals into the UPC or keep them opted out, and whether national courts in Germany and elsewhere will stay infringement proceedings pending UPC revocation actions under Article 33(3) of the UPC Agreement.<\/p>\n\n\n\n

Early UPC Central Division decisions \u2014 there have been a handful of substantive rulings as of the time of writing \u2014 suggest that the UPC is operating with procedural discipline and substantive engagement with validity. The court’s approach to pharmaceutical patent families, including divisional questions, will emerge more clearly over the next two to three years as the case load develops.<\/p>\n\n\n\n

The Political Context<\/strong><\/h3>\n\n\n\n

The European Parliament’s interest in pharmaceutical access and pricing has intensified since the COVID-19 pandemic. The Commission’s 2023 pharmaceutical legislation reform package and the ongoing discussions about compulsory licensing mechanisms reflect a political environment in which originator industry arguments about IP protection have less automatic traction than they once did.<\/p>\n\n\n\n

Divisional cascade strategies have not yet attracted specific legislative attention at the EU level, but the building blocks are in place. The reform package’s transparency provisions, combined with growing awareness of secondary patent strategies among MEPs and healthcare ministers, create a potential path toward specific legislative action on divisional strategy within the patent\/data exclusivity interface \u2014 even if the core EPO rules themselves require EPC amendment.<\/p>\n\n\n\n

The pharmaceutical industry’s lobbying position \u2014 that weakening IP protection will reduce incentives for innovation \u2014 remains influential but is not decisive. The distinction between genuine IP protection and procedural-delay strategy is one that policymakers can understand: most would agree that an originator should be able to protect a genuinely novel invention through divisionals filed in good faith, while most would also agree that filing divisionals known to be invalid simply to delay generic entry is not what the patent system is designed to facilitate.<\/p>\n\n\n\n

Making that distinction legally actionable is the hard part, and it is the challenge that will define pharmaceutical patent policy in Europe for the next decade.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

The divisional cascade strategy exploits a structural feature of the European Patent Convention: the right to file divisional applications from any pending parent, indefinitely, as long as at least one family member remains in prosecution. Pharmaceutical originators use this right not to protect genuinely distinct inventions but to ensure that no court or examining body ever reaches a final adverse decision that enters the public record.<\/p>\n\n\n\n

A final Technical Board of Appeal decision in an EPO case creates citable legal authority that generic manufacturers and national courts can rely on. A pending application creates only legal uncertainty \u2014 and in pharmaceutical patent enforcement, legal uncertainty is commercially equivalent to legal exclusivity, because generic manufacturers and their advisors will not recommend market entry into a legal cloud.<\/p>\n\n\n\n

The economics are unambiguous. Maintaining a divisional cascade costs millions per year. Delaying generic entry in a major European drug franchise generates hundreds of millions per year. The strategy will persist as long as those numbers are true and as long as the EPO’s procedural rules permit it.<\/p>\n\n\n\n

Reform pathways exist but each faces significant obstacles. EPO rule changes are limited by the EPC treaty framework. Competition law intervention requires proving anti-competitive intent in a context where the conduct looks facially legitimate. Transparency improvements help but do not eliminate the underlying legal uncertainty that the strategy exploits. The UPC may accelerate resolution of granted divisionals but does not address pending applications.<\/p>\n\n\n\n

The divisional cascade is not a loophole. It is a deliberate exploitation of features that the EPC’s drafters did not design with pharmaceutical lifecycle management in mind. Understanding it precisely \u2014 in its mechanical, economic, and legal dimensions \u2014 is the prerequisite for any serious engagement with European pharmaceutical patent policy.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q1: Is filing a divisional patent application that is unlikely to succeed a violation of patent law or EPO rules?<\/strong><\/p>\n\n\n\n

No, not under current rules. The EPC grants applicants the right to file divisional applications from any pending parent application (Article 76 EPC). The EPO does not require applicants to assess or certify the likelihood that a divisional will result in a granted patent before filing. Examination is the mechanism through which the EPO filters meritorious from non-meritorious applications. An applicant is entitled to have its application examined, regardless of whether the outcome is likely to be favorable. The strategic timing of divisional filings \u2014 specifically, filing to prevent a final adverse decision from being issued \u2014 is neither prohibited by the EPC nor by the EPO’s Guidelines for Examination. It sits in a legally permissible space that competition law might eventually address but patent law currently cannot.<\/p>\n\n\n\n

Q2: How do generic manufacturers practically assess the risk of pending divisional applications when planning European market entry?<\/strong><\/p>\n\n\n\n

The process typically begins with a comprehensive patent family mapping \u2014 identifying all applications claiming priority from the relevant dates, their prosecution status, divisional relationships, and the scope of pending claims. Patent intelligence services, including DrugPatentWatch, are used to assemble this picture efficiently. Once the family is mapped, outside counsel in each key territory conducts a freedom-to-operate analysis assessing whether the pending claims \u2014 if granted in the form currently claimed \u2014 would likely cover the generic’s proposed product. This analysis is necessarily probabilistic: the generic must assess the likelihood that each pending divisional actually issues, the scope of claims on grant, and the litigation risk if it does. Risk-tolerant generics may launch despite pending divisionals; risk-averse generics (or those with smaller legal budgets) may wait for resolution. The decision is commercial as well as legal.<\/p>\n\n\n\n

Q3: Did the G 4\/19 expanded board decision on double-patenting significantly change the dynamics of divisional cascade strategies?<\/strong><\/p>\n\n\n\n

Partially, but not fundamentally. G 4\/19 confirmed that the EPO will not grant a patent for subject matter identical to a claim already granted in a parent application to the same applicant. This directly prevents one specific tactic: cloning the parent’s granted claims into a divisional to obtain a second patent with a later expiry date. But the decision does not prevent divisionals whose claims are formally different from the parent \u2014 even if the formal difference is minor and the commercial coverage is substantially equivalent. Sophisticated prosecution teams can draft around G 4\/19 by ensuring divisional claims are technically distinct from parent claims, even if the practical effect is near-identical. G 4\/19 reduced the most egregious instances of identical-claim duplication but did not address the broader delay-through-pending-applications strategy.<\/p>\n\n\n\n

Q4: Could EU competition law realistically be used to challenge a divisional cascade strategy in a specific pharmaceutical case?<\/strong><\/p>\n\n\n\n

Theoretically yes, practically difficult. A competition law challenge would need to establish: that the originator holds a dominant position in the relevant product market (typically straightforward for an on-patent branded drug); that the divisional filings constitute “abusive conduct” under Article 102 TFEU; and that they produce an anti-competitive effect. The AstraZeneca precedent establishes that IP office conduct can constitute an abuse, but that case involved affirmative misrepresentations. A divisional cascade involves only the exercise of express procedural rights without misrepresentation. The Commission would need to argue that the purpose \u2014 preventing final decisions rather than protecting genuine inventions \u2014 takes the conduct outside the legitimate exercise of IP rights. This is an arguable case but requires proof of subjective intent or a novel theory of objective abuse that has not been tested at the CJEU level. National competition authorities might be prepared to test this theory in individual cases; the Commission has not done so.<\/p>\n\n\n\n

Q5: With the Unitary Patent system now operational, does the strategic calculus around divisional cascades materially change for originators deciding whether to opt in or opt out?<\/strong><\/p>\n\n\n\n

Opting into the UPC system means that a granted Unitary Patent (or opted-in EP patent) can be revoked centrally by the UPC Central Division in a single proceeding, eliminating it across all participating states simultaneously. This is unfavorable for an originator if it expects the patent to be successfully challenged. The opt-out election during the transitional period allows originators to keep patents subject to national courts only, preserving the fragmented national enforcement landscape that has historically made portfolio challenges expensive. For pending divisional applications \u2014 which are not yet granted and therefore not subject to the opt-out mechanism \u2014 the strategic consideration is different: the originator cannot opt out an application, only a granted patent. If a pending divisional is eventually granted as a Unitary Patent, it is automatically in the UPC system unless the applicant at grant requests national validation instead. The rational strategy for an originator managing a divisional cascade is to pursue national validation rather than Unitary Patent status for divisionals that are expected to be challenged \u2014 keeping those patents in national courts where challenges require separate actions in each country. This nationalization of the divisional landscape is an emerging tactic whose full implications for generic competition are still being assessed by practitioners on both sides.<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/h2>\n\n\n\n

[1] European Patent Convention (EPC), 16th ed. (2023). European Patent Office. Rule 36 EPC: Divisional Applications. https:\/\/www.epo.org\/law-practice\/legal-texts\/epc.html<\/p>\n\n\n\n

[2] Case C-457\/10 P, AstraZeneca AB and AstraZeneca plc v. European Commission, EU:C:2012:770 (Court of Justice of the European Union, 6 December 2012).<\/p>\n\n\n\n

[3] European Patent Office. (2022). EPO Patent Index 2022: Divisional Application Statistics<\/em>. European Patent Office. https:\/\/www.epo.org\/about-us\/annual-reports-statistics.html<\/p>\n\n\n\n

[4] Expanded Board of Appeal, EPO. (2021). Decision G 4\/19 (Double patenting)<\/em>. European Patent Office. https:\/\/www.epo.org\/law-practice\/case-law-appeals\/recent\/g190004ex1.html<\/p>\n\n\n\n

[5] Warner-Lambert Company LLC v Generics (UK) Ltd [2018] EWCA Civ 2228 (Court of Appeal of England and Wales).<\/p>\n\n\n\n

[6] Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, OJ L 311, 28.11.2001.<\/p>\n\n\n\n

[7] European Commission. (2009). Pharmaceutical Sector Inquiry: Final Report<\/em>. European Commission, DG Competition. https:\/\/ec.europa.eu\/competition\/sectors\/pharmaceuticals\/inquiry\/<\/p>\n\n\n\n

[8] Case C-130\/11, Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents, EU:C:2012:489 (Court of Justice of the European Union, 19 July 2012).<\/p>\n\n\n\n

[9] Case C-121\/17, Teva UK Ltd and Others v Gilead Sciences Inc., EU:C:2018:585 (Court of Justice of the European Union, 25 July 2018).<\/p>\n\n\n\n

[10] Case C-650\/17, Royalty Pharma Collection Trust v Deutsches Patent- und Markenamt, EU:C:2020:327 (Court of Justice of the European Union, 30 April 2020).<\/p>\n\n\n\n

[11] European Generic and Biosimilar Medicines Association (EGA). (2023). EGA Market Review: Generics and Biosimilars in Europe 2023<\/em>. EGA. https:\/\/www.egagenerics.com\/publications<\/p>\n\n\n\n

[12] IQVIA Institute for Human Data Science. (2022). Biosimilar Sustainability in Europe: A Five-Country Analysis<\/em>. IQVIA Institute. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports<\/p>\n\n\n\n

[13] Regulation (EU) No 469\/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (codified version), OJ L 152, 16.6.2009.<\/p>\n\n\n\n

[14] European Commission. (2023). Proposal for a Directive of the European Parliament and of the Council on the Union Code Relating to Medicinal Products for Human Use<\/em> (COM\/2023\/192 final). European Commission. https:\/\/health.ec.europa.eu\/medicinal-products\/pharmaceutical-strategy-europe_en<\/p>\n\n\n\n

[15] Agreement on a Unified Patent Court, OJ C 175, 20.6.2013. [Entered into force 1 June 2023.]<\/p>\n\n\n\n

[16] Drahos, P., & Braithwaite, J. (2002). Information Feudalism: Who Owns the Knowledge Economy?<\/em> Earthscan Publications.<\/p>\n\n\n\n

[17] Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA, 316<\/em>(8), 858\u2013871. https:\/\/doi.org\/10.1001\/jama.2016.11237<\/p>\n\n\n\n

[18] Kapczynski, A., Park, C., & Sampat, B. (2012). Polymorphs and prodrugs and salts (oh my!): An empirical analysis of “secondary” pharmaceutical patents. PLOS ONE, 7<\/em>(12), e49470. https:\/\/doi.org\/10.1371\/journal.pone.0049470<\/p>\n\n\n\n

[19] DrugPatentWatch. (2024). Patent family intelligence and pharmaceutical patent tracking platform<\/em>. https:\/\/www.drugpatentwatch.com<\/p>\n\n\n\n

[20] European Patent Office. (2014). Decision of the Administrative Council of 25 March 2014 amending Rules 36, 38 and 135 of the Implementing Regulations to the EPC<\/em> (CA\/D 3\/14). European Patent Office.<\/p>\n\n\n\n

[21] Federal Court of Justice of Germany (Bundesgerichtshof). (2020). Decision Melatonin<\/em> (X ZR 65\/18). Bundesgerichtshof. https:\/\/www.bundesgerichtshof.de<\/p>\n\n\n\n

[22] Mossoff, A. (2019). The patent eligibility mess and administrative law. Patent and Trade Mark Review, 17<\/em>(4), 112\u2013127.<\/p>\n\n\n\n

[23] Hoen, E. F. M. t’, Boulet, P., & Baker, B. K. (2017). Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation. Journal of Pharmaceutical Policy and Practice, 10<\/em>(1), 19. https:\/\/doi.org\/10.1186\/s40545-017-0107-z<\/p>\n\n\n\n

[24] Cremers, K., Ernicke, M., Gaessler, F., Harhoff, D., Helmers, C., McDonagh, L., Schliessler, P., & van Zeebroeck, N. (2017). Patent litigation in Europe. European Journal of Law and Economics, 44<\/em>(1), 1\u201344. https:\/\/doi.org\/10.1007\/s10657-016-9529-0<\/p>\n","protected":false},"excerpt":{"rendered":"

When a European patent dies \u2014 formally, irrevocably, at the hands of the European Patent Office’s Technical Board of Appeal […]<\/p>\n","protected":false},"author":1,"featured_media":37713,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37712"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37712\/revisions"}],"predecessor-version":[{"id":37714,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37712\/revisions\/37714"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37713"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}